FDA Approves At-Home Subcutaneous Injection for Early Alzheimer's

Developed by Eisai and Biogen, the new formulation utilizes an autoinjector to deliver a 500 mg dose, split into two 250 mg injections, each requiring approximately 15 seconds. Clinical data, including sub-studies from the Clarity AD trial, indicate that the subcutaneous method achieves exposure levels equivalent to intravenous delivery, maintaining similar efficacy in amyloid removal while mirroring the safety profile of existing treatments.

For patients and caregivers, this approval serves as a strategy to reduce the logistical burden of frequent clinical visits. According to company research, 94% of study participants found the device easy to handle, fostering greater independence in the treatment journey. The therapy is expected to reach the U.S. market in late August 2026, where it will be available via specialty pharmacies alongside existing support programs designed to manage insurance coverage and financial assistance.